MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
DarioHealth Corp. Operating Income 2011-2026 | DRIO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income DarioHealth Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -36.7 M | -57.7 M | -56.2 M | -56.8 M | -76.5 M | -29.9 M | -17.7 M | -17.7 M | -14.4 M | -11.1 M | -7.7 M | -11.4 M | -13.6 M | -3.97 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.97 M | -76.5 M | -29.4 M |
Quarterly Operating Income DarioHealth Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.48 M | -9.2 M | -9.41 M | - | -12 M | -16.2 M | -17.9 M | - | -15.5 M | -14 M | -12.4 M | - | -14.6 M | -17.4 M | -15.9 M | - | -22.5 M | -18 M | -14.3 M | - | -6.6 M | -4.12 M | -10.1 M | - | -2.8 M | -5.36 M | -5.36 M | - | -4.05 M | -5.79 M | -2.92 M | - | -2.98 M | -4.12 M | -4.2 M | - | -2.72 M | -2.62 M | -1.92 M | - | -2.55 M | -1.51 M | -1.78 M | - | -2.51 M | -3.6 M | -2.67 M | - | -3.24 M | -3.6 M | -3.08 M | - | -1.02 M | -866 K | -495 K | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -495 K | -22.5 M | -7.41 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.35 B | $ 115.69 | 0.13 % | $ 35.2 B |  USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Illumina
ILMN
|
-833 M | $ 128.66 | 0.61 % | $ 20.5 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Co-Diagnostics
CODX
|
-50.2 M | $ 1.66 | -0.9 % | $ 2.21 M | USA |
 |
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 84.24 | -0.11 % | $ 5.69 B | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 417.83 | 1.78 % | $ 12.1 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 24.81 | 1.43 % | $ 689 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 27.56 | 0.31 % | $ 20 B |  Niderland |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M |  Israel |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 21.33 | 0.47 % | $ 1.14 B | USA |
 |
Senseonics Holdings
SENS
|
-68.3 M | $ 7.17 | 1.7 % | $ 299 M | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Soleno Therapeutics
SLNO
|
9.41 M | $ 52.75 | 0.06 % | $ 2.68 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 15.7 | -3.74 % | $ 475 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Thermo Fisher Scientific
TMO
|
7.75 B | $ 467.48 | -0.45 % | $ 176 B | USA |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Trinity Biotech plc
TRIB
|
6.62 M | $ 0.64 | -0.83 % | $ 61.9 M |  Irlanda |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 171.6 | 1.08 % | $ 8.51 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-136 M | $ 61.18 | 0.39 % | $ 3.66 B | USA |
 |
Guardant Health
GH
|
-437 M | $ 89.01 | 0.11 % | $ 11.2 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
4.08 M | $ 1.93 | -2.08 % | $ 8.54 M | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | Niderland |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.58 | 0.42 % | $ 2.08 B | USA |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.15 | 0.7 % | $ 4.94 M | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 17.19 | -0.23 % | $ 385 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 101.81 | -0.35 % | $ 8.4 B | Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 263.75 | - | $ 21.9 B | USA |
 |
Celcuity
CELC
|
-172 M | $ 124.21 | 2.62 % | $ 5.81 B | USA |
 |
OpGen
OPGN
|
325 K | - | -16.95 % | $ 1.54 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 8.48 | 2.29 % | $ 1.09 B | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 4.79 | 0.21 % | $ 444 M | USA |
 |
Natera
NTRA
|
-541 M | $ 204.22 | 0.23 % | $ 20.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 196.35 | 0.07 % | $ 21.8 B | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
PerkinElmer
PKI
|
357 M | - | -0.91 % | $ 14.7 B | USA |